1Sato M, Kondoh M. Recent studies on metallothionein: protection againsttoxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med,2002, 196 (1): 9-22.
2Santon A, Albergoni V, Stumiolo GC et al. Evaluation of MT expression and detection of apoptotic cells in LEC rat kidneys. Biochim Biophys Acta,2004, 1688 (3): 223 -231.
3Ioachim EE, Kstsiou E, Carassavoglou C et al. Immunohistochemical localization of metallothionein in endometrial lesions. J Pathol, 2000, 191 :269 - 273.
4Espey LL, Ujioka T, Okamum H et al. Metallothionein - 1 messenger RNA transcription in steroid - secreting cells of the rat ovary during the periovulatory period. Biol Reprod, 2003, 68 : 1895 - 1902.
5McCluggage WG, Strand K, Abdulkadir A.. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer, 2002, 12 (1) : 62 -65.
8McCluggage WG, Maxwell P, Bharucha H. Immunohistochemical detection of metallothionein and MIB1 in uterine cervical squamous lesions. Int J Gynecol Pathol, 1998, 17 ( 1 ) : 29 - 35.
9Azuma Y, Chou SC, Lininger RA et al. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix : pimonidazole and involucrin. Clin Cancer Res, 2003, 9 (13) : 4944 -4952.
10Hainaut P, Mann K. Zinc binding and redox control of p.53 structure and function. Antioxid Redox Signal, 2001, 3:611 -623.
二级参考文献7
1茹炳根.第4届国际金属硫蛋白会议简介[J].生命科学,1998,10:157-157.
2[1]Hengstler JG,Pilch H,Schmidt M,et al.Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis.Int J Cancer,2001,95(2:121-127
3[2]Kikuchi Y,Hirata J,Yamamoto K,et al.Altered expression of gamma-glutamylcysteine,metallothionein and topoisomerase Ⅰ or Ⅱ during acquisition of drug resistance to cisplatin in human ovarian cancer cells.Jpn J Cancer Res,1997,88(2:213-217
4[3]Hiroshi U,Hajime H,Tsuyoshi I,et al.Overexpression of resistance-related proteins(metallothionein,glutathione-s-transferase π,heat shock protein 27,and lung resistance-related protein)in osteosarcoma.Cancer,1997,79(12:2336-2344
5[4]Kolfschoten GM,Hulscher TM,Pinedo HM,et al.Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografes.Br J Cancer,2000,83(7):921-927
6[5]Goff BA,Paley PJ,Greer BE,et al.Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.Gynecol Oncol,2001,81(1:18-24
7[6]Brinkhwis M,Izquierdo MA,Baak JP,et al.Expression of multidrug resistance-associated markers,their relation to quantitative pathologic tumor characteristics and prognosis in advanced ovarian cancer.Anal Cell Pathol,2002,24(1:17-23
